{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    6,
    7,
    20,
    25,
    26,
    34,
    41,
    45,
    47,
    48,
    49,
    50,
    52,
    54
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "SoA and Screening Procedures Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.3",
        "sectionTitle": "Schedule of Activities (SoA), Table 1",
        "description": "Reference from the amendment summary to Table 1, noting the addition of a footnote about screening procedures detailed in Section 8."
      },
      {
        "id": "ref_2",
        "name": "Screening Site Procedures Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8",
        "sectionTitle": "Study Assessments and Procedures",
        "description": "Reference from the amendment summary to Section 8 for details on procedures specific to screening-only sites in the US."
      },
      {
        "id": "ref_3",
        "name": "COVID-19 Vaccine Risk Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.5",
        "sectionTitle": "COVID-19 Vaccine Risk Assessment",
        "description": "Reference to Section 10.5 for potential risks and mitigation measures related to the COVID-19 vaccine."
      },
      {
        "id": "ref_4",
        "name": "Investigator's Brochure Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "N/A",
        "sectionTitle": "Investigator’s Brochure (IB)",
        "description": "Reference to the Investigator's Brochure (IB) for data on ALXN1840 and ammonium tetrathiomolybdate."
      },
      {
        "id": "ref_5",
        "name": "Dose Modification Reference from Risk Table",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.6",
        "sectionTitle": "Dose Modification",
        "description": "Reference from Table 3 to Section 6.6 for dose modification or discontinuation strategies."
      },
      {
        "id": "ref_6",
        "name": "Adaptive Features Table Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 4",
        "sectionTitle": "Adaptive Protocol Features",
        "description": "Reference to Table 4 for a description of adaptive design features and their limits."
      },
      {
        "id": "ref_7",
        "name": "Dose Modification Criteria Table Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 7",
        "sectionTitle": "ALXN1840 Dose Modifications for Individual Participants",
        "description": "Reference from Table 4 to Table 7, which outlines criteria for dose modification."
      },
      {
        "id": "ref_8",
        "name": "Screening Exclusion Criteria Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.2",
        "sectionTitle": "Exclusion Criteria",
        "description": "Reference from lifestyle considerations to Section 5.2 regarding exclusion due to blood donation."
      },
      {
        "id": "ref_9",
        "name": "Contraceptive Methods Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.4",
        "sectionTitle": "Contraceptive Guidance and Collection of Pregnancy Information",
        "description": "Reference to Section 10.4 for descriptions of appropriate contraceptive methods."
      },
      {
        "id": "ref_10",
        "name": "Contraceptive Start Time Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.1",
        "sectionTitle": "Inclusion Criteria",
        "description": "Reference to Section 5.1 for information on start times for contraceptive use."
      },
      {
        "id": "ref_11",
        "name": "Discontinuation Data Collection Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.3",
        "sectionTitle": "Schedule of Activities (SoA)",
        "description": "Reference to the SoA for data to be collected at the time of study intervention discontinuation."
      },
      {
        "id": "ref_12",
        "name": "Dose Modification for Liver Function Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.6",
        "sectionTitle": "Dose Modification",
        "description": "Reference to dose modification criteria in Section 6.6 for participants with abnormal liver function."
      },
      {
        "id": "ref_13",
        "name": "Pregnancy Discontinuation Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.2.6",
        "sectionTitle": "Pregnancy",
        "description": "Reference to Section 8.2.6 regarding discontinuation due to pregnancy."
      },
      {
        "id": "ref_14",
        "name": "Discontinuation Samples Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 1",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference to the SoA (Table 1) for samples and data to be collected at the time of study intervention discontinuation."
      },
      {
        "id": "ref_15",
        "name": "ECG Schedule Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.3",
        "sectionTitle": "Schedule of Activities (SoA)",
        "description": "Reference to the SoA for the schedule of 12-lead ECGs."
      },
      {
        "id": "ref_16",
        "name": "QTc Withdrawal Criteria Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7",
        "sectionTitle": "DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT DISCONTINUATION/WITHDRAWAL",
        "description": "Reference to Section 7 for QTc withdrawal criteria."
      },
      {
        "id": "ref_17",
        "name": "Clinical Lab Tests Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.2",
        "sectionTitle": "Clinical Laboratory Tests",
        "description": "Reference to Section 10.2 for the list of clinical laboratory tests and to the SoA (Section 1.3) for timing."
      },
      {
        "id": "ref_18",
        "name": "AE/SAE Procedures Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.3",
        "sectionTitle": "Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting",
        "description": "Reference to Section 10.3 for procedures on recording, evaluating, and reporting AEs and SAEs."
      },
      {
        "id": "ref_19",
        "name": "Lost to Follow-up Definition Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.3",
        "sectionTitle": "Lost to Follow-up",
        "description": "Reference to Section 7.3 for the definition of lost to follow-up."
      },
      {
        "id": "ref_20",
        "name": "Genetic Testing Non-use Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.7",
        "sectionTitle": "Genetics",
        "description": "Reference to Section 8.7 to clarify that biobanked samples will not be used for genetic testing."
      },
      {
        "id": "ref_21",
        "name": "PK Sample Collection Schedule Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 1",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference to the SoA (Table 1) for the schedule of whole blood sample collection for PK analysis."
      },
      {
        "id": "ref_22",
        "name": "Molybdenum Measurement Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.1.1",
        "sectionTitle": "Copper and Molybdenum Balance Measurements",
        "description": "Reference to Section 8.1.1 for details on molybdenum measurement in food, drinks, urine, and feces."
      },
      {
        "id": "ref_23",
        "name": "Biomarker Details Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.6",
        "sectionTitle": "Pharmacodynamics",
        "description": "Reference to Section 8.6 for details on biomarker measurements like total copper and ceruloplasmin."
      },
      {
        "id": "ref_24",
        "name": "Analysis Populations Table Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 8",
        "sectionTitle": "Populations for Analysis",
        "description": "Reference to Table 8 for definitions of the population sets used for analyses."
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "To align the number of days with the mention of zinc discontinuation elsewhere in the protocol.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE",
        "pageNumber": 3
      },
      {
        "id": "annot_2",
        "text": "To facilitate participant recruitment across different regions of the US and to lessen inconvenience for participants without compromising the quality of the study.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE",
        "pageNumber": 3
      },
      {
        "id": "annot_3",
        "text": "Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; IB = Investigator’s Brochure; PK = pharmacokinetics; WD = Wilson disease.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 3: Potential Risks and Mitigation Strategy",
        "pageNumber": 21
      },
      {
        "id": "annot_4",
        "text": "Abbreviations: CRF = case report form; CRU = clinical research unit; EOS = End of Study; SoA = Schedule of Activities.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 5: Participant Lifestyle Considerations",
        "pageNumber": 35
      },
      {
        "id": "annot_5",
        "text": "Abbreviations: ICF = informed consent form; PD = pharmacodynamic; PK = pharmacokinetic.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 8: Populations for Analysis",
        "pageNumber": 51
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "Original",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-05-12",
        "description": "Original Protocol"
      },
      {
        "id": "ver_2",
        "versionNumber": "1.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-08-18",
        "description": "Protocol Amendment 1",
        "amendmentNumber": "Amendment 1"
      },
      {
        "id": "ver_3",
        "versionNumber": "2.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-03-19",
        "description": "Protocol Amendment 2",
        "amendmentNumber": "Amendment 2"
      },
      {
        "id": "ver_4",
        "versionNumber": "3.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-08-31",
        "description": "Protocol Amendment 3",
        "amendmentNumber": "Amendment 3"
      },
      {
        "id": "ver_5",
        "versionNumber": "3.1 (US)",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2022-03-18",
        "description": "Protocol Amendment 3.1 specific to the US to clarify study procedures and facilitate recruitment.",
        "amendmentNumber": "Amendment 3.1 (US)"
      }
    ],
    "summary": {
      "referenceCount": 24,
      "annotationCount": 5,
      "versionCount": 5
    }
  }
}